Page 233 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 233
Optimal timing and response criteria of Interim-PET in DLBCL
Time to Progression
Supplemental Table 7. HRs for DS4-5, DS5 and ∆SUVmax PET response criteria with 2-year TTP as outcome.
Timing DS1-3 vs 4-5
HR (95% CI)
1 1.23 (0.43-3.65)
2 1.72 (1.30-2.28)
3 2.07 (0.55-7.83)
4 3.05 (1.99-4.67)
Abbreviations are explained in Table 1.
DS1-4 vs 5
HR (95% CI) 3.03 (1.10-8.36) 5.06 (3.45-7.41) 1.54 (0.20-12.08) 6.44 (3.62-11.44)
∆SUVmax
HR (95% CI) 1.76 (0.44-7.04) 2.98 (2.15-4.11) 0.76 (0.10-6.00) 4.58 (2.60-8.06)
Supplemental Table 8. PPV and NPV for DS4-5, DS5 and ∆SUVmax PET response criteria at I-PET2 and I-PET4 with 2-year TTP as outcome.
I-PET criteria
I-PET2 DS1-3 vs 4-5 DS1-4 vs 5
∆SUVmax I-PET4 DS1-3 vs 4-5
DS1-4 vs 5 ∆SUVmax
Abbreviations are explained in Table 2.
PPV (95% CI)
26.5 (22.3-30.6) 63.8 (51.6-76.1) 40.8 (32.5-49.0) 39.4 (29.9-48.8) 67.0 (48.2-85.8) 52.5 (36.2-68.8)
NPV (95% CI)
85.5 (82.7-88.2) 82.9 (80.6-85.3) 83.6 (81.2-86.0) 86.6 (83.2-90.0) 83.6 (80.2-87.0) 84.2 (80.1-88.2)
Supplemental Table 9. HRs between negative I-PET timings and between positive I-PET timings compared to I-PET2 with 2-year TTP as outcome.
I-PET1 negative I-PET2 negative I-PET3 negative I-PET4 negative I-PET1 positive I-PET2 positive I-PET3 positive I-PET4 positive
DS1-3 vs 4-5 (95% CI)
1.31 (0.53-3.26) 1 (reference) 0.97 (0.47-2.00) 0.73 (0.51-1.03) 0.94 (0.51-1.76) 1 (reference) 1.17 (0.37-3.68) 1.29 (0.88-1.87)
DS1-4 vs 5 (95% CI)
1.00 (0.53-1.91) 1 (reference) 0.97 (0.51-1.84) 0.78 (0.59-1.03) 0.60 (0.25-1.44) 1 (reference) 0.30 (0.04-2.18) 0.99 (0.52-1.86)
∆SUVmax (95% CI)
0.86 (0.32-2.32) 1 (reference) 1.09 (0.55-2.13) 0.76 (0.55-2.13) 0.51 (0.18-1.41) 1 (reference) 0.28 (0.04-2.00) 1.17 (0.67-2.07)
Abbreviations are explained in Supplemental Table 5.
231
8
